WSTAM
ALXN

Wilbanks Smith & Thomas Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-282
Closed -$39K – 1455
2018
Q3 		$39K Buy
+282
New +$35.4K ﹤0.01% 736

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ALXN Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 282 shares — an estimated $39K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ALXN in Q3 2018 and held it in 1 quarter. The position peaked at $39K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 282 Alexion Pharmaceuticals shares in Q4 2018, an estimated $39K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Alexion Pharmaceuticals position peaked at $39K in Q3 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.